Physician profile
Paul E Gebhard
NPI 1821187204
$1,039.71
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $149 · 2022: $15.15 · 2023: $12.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $109.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.68 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.84 | 2019-2020 | |
| Novo Nordisk INC | $86.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $86.59 | 2019 | |
| Glaxosmithkline, LLC. | $84.58 | 2019-2020 | |
| Pfizer INC. | $76.23 | 2019-2020 | |
| Abbvie INC. | $64.58 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $50.83 | 2019-2020 | |
| Amarin Pharma, INC. | $45.34 | 2019-2020 | |
| Astellas Pharma US INC | $35.86 | 2019 | |
| Amgen INC. | $32.60 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $31.57 | 2019 | |
| Supernus Pharmaceuticals, INC. | $24.74 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.07 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $22.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.85 | 2019 | |
| Lilly USA, LLC | $17.44 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gebhard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.